scholarly journals Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer

2021 ◽  
Vol 15 (1) ◽  
pp. 11-15
Author(s):  
Dalia O. Mohamed ◽  
Mona M. Sayed ◽  
Islam F. Abdelkawi ◽  
Mahmoud H. Elshoieby ◽  
Salah M. Khallaf ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Squamous Cell ◽  
Transitional Cell ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Muscle Invasive

scholarly journals Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer: What Is the Real Impact of Squamous Cell Carcinoma Variant on Oncological Outcomes?

Medicina ◽  
2022 ◽  
Vol 58 (1) ◽  
pp. 90
Author(s):  
Guglielmo Mantica ◽  
Francesco Chierigo ◽  
Rafaela Malinaric ◽  
Salvatore Smelzo ◽  
Francesca Ambrosini ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cox Regression ◽  
Disease Recurrence ◽  
Intravesical Therapy ◽  
Regression Analyses ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Background and Objectives: To evaluate the oncological impact of squamous cell carcinoma (SCC) variant in patients submitted to intravesical therapy for non-muscle-invasive bladder cancer (NMIBC). Materials and Methods: Between January 2015 and January 2020, patients with conventional urothelial NMIBC (TCC) or urothelial NMIBC with SCC variant (TCC + SCC) and submitted to adjuvant intravesical therapies were collected. Kaplan–Meier analyses targeted disease recurrence and progression. Uni- and multivariable Cox regression analyses were used to test the role of SCC on disease recurrence and/or progression. Results: A total of 32 patients out of 353 had SCC at diagnosis. Recurrence was observed in 42% of TCC and 44% of TCC + SCC patients (p = 0.88), while progression was observed in 12% of both TCC and TCC + SCC patients (p = 0.78). At multivariable Cox regression analyses, the presence of SCC variant was not associated with higher rates of neither recurrence (p = 0.663) nor progression (p = 0.582). Conclusions: We presented data from the largest series on patients with TCC and concomitant SCC histological variant managed with intravesical therapy (BCG or MMC). No significant differences were found in term of recurrence and progression between TCC and TCC + SCC. Despite the limited sample size, this study paves the way for a possible implementation of the use of intravesical BCG and MMC in NMIBC with histological variants.

Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 264-264 ◽  
Author(s):  
Raymond H. Mak ◽  
Daniel Hunt ◽  
William U. Shipley ◽  
Jason Alexander Efstathiou ◽  
William J. Tester ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Combined Modality Therapy ◽  
Transitional Cell ◽  
Pooled Analysis ◽  
Long Term Outcomes ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

264 Background: Multiple prospective RTOG studies have evaluated bladder preserving combined-modality therapy (CMT) including local resection with chemo-radiation for the treatment of muscle invasive bladder cancer (MIBC) reserving cystectomy for salvage. Here we report a pooled analysis of long-term outcomes. Methods: We performed a pooled analysis of 468 patients (pts) with MIBC enrolled on six RTOG bladder preservation studies, including five Phase II studies: RTOG 8802, 9506, 9706, 9906, and 0233, and one phase III study: 8903. Overall survival (OS) was estimated with the Kaplan-Meier method, and disease specific survival (DSS), local failure (LF) and distant metastasis (DM) were estimated by the cumulative incidence method. Results: The median age of the pts was 66 (range, 34-93), and the majority had a Zubrod performance status (PS) of 0 (89.1%). The most common tumor histology was transitional cell carcinoma (94.2%). Clinical tumor stage distribution included 60.6% T2, 29.1% T3a, 6.2% T3b, and 3.9% T4a. A complete response to CMT was observed in 72.0% of pts. With a median follow-up of 4.29 years among all pts, and 7.80 years among survivors (n=205), the 5-year and 10-year results were as follows (Table). Examining outcomes by subgroups, higher clinical T-stage (T2 vs. T3/T4) was associated with decreased DSS (5-year DSS: 74% vs. 66%; 10-year DSS: 69% vs. 60%; p=0.05), and OS (5-year OS: 62% vs. 49%; 10-year OS: 41% vs. 30%; p=0.002). On multivariate analysis, after adjusting for age and PS, higher T-stage was associated with decreased DSS (Hazard ratio: 1.65; 95% confidence interval: 1.19-2.27; p=0.002). Among pts with non-transitional cell carcinoma histology (n=29), the 5-year and 10-year DSS was 66% and 60%, respectively, and 5-year and 10-year OS was 41% and 21%. Conclusions: This pooled analysis of RTOG trials of bladder preserving CMT for MIBC demonstrates long-term OS and DSS comparable to modern immediate cystectomy-based strategies with and without neoadjuvant chemotherapy. CMT can be considered as an alternative to radical cystectomy in selected pts. [Table: see text]

Prognostic impact of percentage of squamous differentiation in patients with nonbilharzial squamous cell carcinoma and transitional cell carcinoma treated with radical cystectomy.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 498-498 ◽  
Author(s):  
Marine Slim ◽  
Eva Comperat ◽  
Morgan Roupret ◽  
Jerome Parra ◽  
Jean-Marc Simon ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Squamous Cell ◽  
Bladder Carcinoma ◽  
Transitional Cell ◽  
Prognostic Impact ◽  
Squamous Differentiation ◽  
Cancer Specific Survival

498 Background: Squamous differentiation has been reported to occur in 10-22 % of transitional cell carcinoma. The prognostic impact of squamous differentiation is controversial. In addition, it remains unclear whether the percentage of squamous differentiation impact outcome of patients with nonbilharzial squamous cell carcinoma and transitional cell carcinoma treated with radical cystectomy Methods: We performed a retrospective study of patients with non-bilharzial squamous variants or squamous bladder carcinoma treated in two French institutions. The percentage of squamous differentiation was determined by an expert GU pathologist on radical cystectomy specimens. Progression-free survival (PFS) and cancer-specific survival (CSS) were analyzed according to the percent of squamous differentiation. Survivals were estimated using the Kaplan-Meier method and compared using multivariate Cox proportional hazard regression analysis. Results: Forty patients were identified including 28 and 12 patients which tumors were classified as transitional cell carcinomas cases with squamous cell differentiation and pure non-bilharzial squamous bladder carcinoma, respectively. Patients with tumors harboring more than 50% of squamous differentiation had a PFS of 6.3 months as compared to 60.2 months for those with squamous differentiation present in less than 50% (p = 0.014). In multivariate analysis, the percentage of squamous differentiation was the only independent prognostic factor for PFS (HR = 2.63 (IC 95%: 1.22-5.67). First site of recurrence of patients with squamous differentiation ≥50% were more frequently the pelvis (72% versus 17 %; p = 0.049). No difference in CSS were observed between patients with tumors < 50% or ≥50% squamous differentiation (16.3 months versus 62 months) (p = 0.2). Conclusions: Extensive squamous differentiation in bladder cancer is associated with poor PFS and pelvic progression, suggesting that those patients might benefit from adjuvant pelvic radiotherapy. Larger studies are needed to validate these findings.

Effect of age and gender on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive transitional cell carcinoma of the bladder: A retrospective study of 50 patients treated with radical cystectomy.

2019 ◽  
Vol 37 (8_suppl) ◽  
pp. 65-65
Author(s):  
Shaheen Riadh Alanee ◽  
Bradley Holland ◽  
Kristin Delfino ◽  
Danuta Dynda
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Transitional Cell ◽  
Female Gender ◽  
Immune Markers ◽  
Node Metastasis ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

65 Background: Older age and female gender have been associated with worse outcomes in patients with muscle invasive bladder cancer undergoing radical cystectomy. Reduced immune response has been implicated in disease metastasis and worse survival. The objective of our study was to determine the expression patterns of various cellular proteins active in immune pathways in bladder cancer patients, and assess the correlation between age, gender, and expression of these immune markers. Methods: Tissue samples were obtained from equally distributed male/female patients with/without lymph node metastasis on final pathology after undergoing radical cystectomy for transitional cell carcinoma (TCC) of the bladder from 2009-2011 (n = 50). Immunohistochemistry (IHC) for CD3, CD4, CD8, LAG3, CD56, TIM3, PD-1 and PD-L1 were performed and scored by a single pathologist (scoring was on 0 to 100% scale). Statistical analyses investigated association between age, gender, lymph node metastasis, and IHC results. Results: Mean age at surgery was 67 yrs (range 50 to 78 yrs); all patients were Caucasians. Statistical analyses showed no association between patients' age, gender, and the expression of any of the immune markers (p > 0.05). Similarly, the staining scores for the immune markers were not noted to be correlated with LN metastasis. Correlation between stains showed a negative correlation between CD56 and PD-L1 (-0.286, p = 0.047) and between PD-1 and PD-L1 (-0.381, p = 0.007). Conclusions: Although age and female gender have been associated with worse outcomes in bladder cancer, this association may be independent of the immune pathways active in the disease. Increased expression of PD-L1 is associated significantly with suppression of anti-tumor natural killer cells in the transitional cell carcinoma of the bladder.

scholarly journals Bladder squamous cell carcinoma in a pregnant woman: case report and review of the literature

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Pablo A. Rojas ◽  
Cristián González ◽  
Gonzalo P. Mendez ◽  
Alejandro Majerson ◽  
Ignacio F. San Francisco
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Pregnant Woman ◽  
Urinary Tract ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Squamous Cell ◽  
Pet Ct ◽  
Cell Bladder Cancer ◽  
Urinary Tract Reconstruction

Abstract Background Bladder tumors in pregnancy are extremely rare. No more than 50 cases have been published to date, including all histologic variants, and only three cases of bladder squamous cell carcinoma have been described. Case presentation We present a clinical case of a 31-year-old woman with bladder squamous cell carcinoma in the second trimester of pregnancy. After a C-section at 30 weeks, we performed radical cystectomy with extended bilateral lymphadenectomy, hysterectomy and right oophorectomy. The Studer neobladder technique was performed for urinary tract reconstruction. Definitive pathology showed invasive bladder squamous cell carcinoma, Grade 2, with microscopic infiltration of the perivesical fat, negative margins, and 3/28 lymph nodes with carcinoma (pT3aN2M0). The patient underwent 18 months of surveillance after radical cystectomy, without recurrence by PET-CT. Conclusions Bladder cancer in pregnant women is extremely rare but must be considered in those with recurrent gross hematuria and/or recurrent urinary tract infection. To our knowledge, this case involves the longest recurrence-free survival of a pregnant woman with squamous cell bladder cancer published thus far.

Sign in / Sign up

Export Citation Format

Share Document